# FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor

> **NCT00660582** · PHASE2 · COMPLETED · sponsor: **Per Pfeiffer** · enrollment: 152 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Cetuximab (Erbitux)
- **DRUG:** Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid

## Key facts

- **NCT ID:** NCT00660582
- **Lead sponsor:** Per Pfeiffer
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2011-05
- **Final completion:** 2013-02
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2015-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00660582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00660582, "FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00660582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*